Disease · HP_0100543

Cognitive impairment

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Cognitive impairment. Diseases, record HP_0100543. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100543

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Cognitive impairment
Open Targets ID: HP_0100543
Other names: Abnormality of cognition, Cognitive abnormality, Cognitive defects, Cognitive deficits, Intellectual impairment
Highest stage of its drugs: Approval, for 8 of its 247 drugs, from DailyMed, PMDA and TTD

Source Open Targets

Drugs247

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLORBETAPIR F 18	CHEMBL1774461	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
FLORTAUCIPIR F 18	CHEMBL3545253	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
FLUTEMETAMOL F 18	CHEMBL2042122	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
DONANEMAB	CHEMBL4297245	Antibody	Approval	PMDA	1	0	0	Drugs and targets
FLORBETABEN F18	CHEMBL566752	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
IDEBENONE	CHEMBL252556	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LECANEMAB	CHEMBL3833321	Antibody	Approval	PMDA	1	0	0	Drugs and targets
PIRACETAM	CHEMBL36715	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DONEPEZIL	CHEMBL502	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets

1 to 10 of 247

See all 247 drugs

Targets259

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Sodium-dependent serotonin transporter	7	Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
ACHE	Acetylcholinesterase	6	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/43	Drugs and targets
ADRA2A	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
DRD2	D(2) dopamine receptor	6	Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptor agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
GABRA1	GABA-A receptor; agonist GABA site	6	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; agonist GABA site	6	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; agonist GABA site	6	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; agonist GABA site	6	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets

1 to 10 of 259

See all 259 targets

Trials226

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01739933	The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure	Phase 3	438	2021-06-07	Sepsis, Delirium, Impaired Cognition	DEXMEDETOMIDINE, PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT02822573	Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil	Phase 3	276	2023-09-13	Cognitive Dysfunction, Memory Impairment	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT01767909	The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)	Phase 2/3	240	2020-05-18	Amnestic Mild Cognitive Impairment, Alzheimer's Disease	INSULIN HUMAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00000392	Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.	Phase 2	215	2015-08-04	HIV Infections, Cognition Disorders	PEPTIDE T	Its record names the disease	ClinicalTrials.gov
NCT02953639	A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics	Phase 2	214	2021-02-09	Schizophrenia	BASMISANIL	Its record names the disease	ClinicalTrials.gov
NCT01984164	CAndesartan vs LIsinopril Effects on the BRain	Phase 2	176	2021-02-21	Hypertension, Mild Cognitive Impairment	CANDESARTAN, LISINOPRIL ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT00040443	Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.	Phase 2	175	2018-07-23	Mild Cognitive Impairment	CX516	Open Targets' reading of its record	ClinicalTrials.gov
NCT02008773	A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia	Phase 2	170	2019-01-30	Schizophrenia	VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00853580	A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1	Phase 2	146	2018-03-12	Neurofibromatosis Type 1	LOVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00361257	Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults	Phase 2	107	2011-07-26	HIV Infections	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 226

See all 226 trials

Comparisons in its trials65

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dexmedetomidine vs Propofol: Death at 90 Days	81 of 214	82 of 208	422	NCT01739933	Trial comparisons
Dexmedetomidine vs Propofol: deaths from any cause	89 of 214	86 of 208	422	NCT01739933	Trial comparisons
Dexmedetomidine vs Propofol: serious adverse events	0 of 214	0 of 208	422	NCT01739933	Trial comparisons
Donepezil vs Placebo: deaths from any cause	0 of 140	0 of 136	276	NCT02822573	Trial comparisons
Donepezil vs Placebo: serious adverse events	12 of 140	8 of 136	276	NCT02822573	Trial comparisons
Insulin (Humulin® R U-100) vs Placebo: deaths from any cause	1 of 121	0 of 119	240	NCT01767909	Trial comparisons
Insulin (Humulin® R U-100) vs Placebo: serious adverse events	18 of 121	10 of 119	240	NCT01767909	Trial comparisons
Peptide T vs Placebo: serious adverse events	8 of 106	3 of 109	215	NCT00000392	Trial comparisons
Candesartan vs Lisinopril: deaths from any cause	0 of 87	0 of 89	176	NCT01984164	Trial comparisons
Candesartan vs Lisinopril: serious adverse events	0 of 87	0 of 89	176	NCT01984164	Trial comparisons

1 to 10 of 65

See all 65 comparisons in its trials

Papers from its trials119

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36048943	RESULT	1	PubMed
34813630	RESULT	1	PubMed
33894597	RESULT	1	PubMed
33282811	RESULT	1	PubMed
33030307	RESULT	1	PubMed
32854852	RESULT	1	PubMed
32559474	RESULT	1	PubMed
32352644	RESULT	1	PubMed
32317958	RESULT	1	PubMed
32178931	RESULT	1	PubMed

1 to 10 of 119

See all 119 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100543

GET https://conductscience.org/api/diseases/v1/HP_0100543/drugs?page=2

API reference For AI assistants